The main drivers are to increase productivity, cut costs, address capacity limits, and resolve downstream bottlenecks. In many cases, these changes are made within existing facilities, without a full process redesign.

It works best when it s focused on the steps that matter most. Early choices can bring big gains, but they re hard (and costly) to undo. Decisions should be guided by process data, risk tolerance, and regulatory considerations.

It works well for monoclonal antibodies and other proteins with large patient populations. It s especially useful for biosimilars to lower costs. Intensification could also be a good fit when a producer cell line is used to make viral vectors for common diseases.

Risk is lower when teams focus on a few key steps instead of changing everything. Using fewer manual steps and proven, integrated equipment also helps. A clear, structured approach helps reduce variation, avoid deviations, and keep output consistent.

Yes. Let s discuss your vision and how to execute on it quickly and taking all factors into account. We can even support you with process development services while we re building your modular solution.